Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.43 |
| ▸ | PTAFR | P25105 | 7/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6149148 | 0.84 | CNR2 (0.44) | RPS6KA5CNR2PTGER4BRD4 | |
| Hydrochloric Acid SCHEMBL6149568 | 0.82 | CNR2 (0.49) | RPS6KA5CNR2PTGER4BRD4 | |
| Hydrochloric Acid SCHEMBL6153277 | 0.80 | PDE4B (0.37) | RPS6KA5CNR2BRD4CYP2D6 | |
| SCHEMBL14252550 | 0.77 | RPS6KA5 (0.69) | RPS6KA5 | |
| SCHEMBL4126037 | 0.77 | RPS6KA5 (0.60) | RPS6KA5CYP2D6CCR5 | |
| SCHEMBL6157116 | 0.74 | GPR119 (0.48) | CNR2 | |
| SCHEMBL13834686 | 0.74 | ATM (0.46) | RPS6KA5PTGER4BRD4 | |
| SCHEMBL8130054 | 0.73 | PTGER4 (0.43) | PTAFRPTGER4BRD4CYP2D6CCR5 | |
| SCHEMBL8136476 | 0.73 | LMNA (0.44) | — | |
| SCHEMBL8120303 | 0.72 | CACNA2D1 (0.53) | BRD4CYP2D6CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738269-B1 | PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | URIACH & CIA SA J (ES) | 2000-04-26 | — | — | EP | claimed |
| US-5705504-A | PLATELET ACTIVATING FACTOR | J. URIACH & CIA, S.A. (ES) | 1998-01-06 | — | — | US | claimed |
| EP-0738269-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-10-23 | — | — | EP | claimed |
| WO-1996014317-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-05-17 | — | — | WO | claimed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
| EP-0790998-B1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | URIACH & CIA SA J (ES) | 2001-01-17 | — | — | EP | disclosed |
| EP-0738269-B1 | PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | URIACH & CIA SA J (ES) | 2000-04-26 | — | — | EP | disclosed |
| US-5747477-A | INFLAMMATORY BOWEL DISEASE, GASTROINTESTINAL DISORDERS, CROHN*S DISEASE | J. URIACH & CIA S.A. (ES) | 1998-05-05 | — | — | US | disclosed |
| US-5705504-A | PLATELET ACTIVATING FACTOR | J. URIACH & CIA, S.A. (ES) | 1998-01-06 | — | — | US | disclosed |
| WO-1997009329-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | RPS6KA5 1539/4885PTAFR 964/4885CNR2 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.